Sky Labs Inc.
- Industry
- Medical Devices & Equipment
- Founded Year
- 2015
- Headquarters
- Seongnam-si, Gyeonggi-do, South Korea
- Employee Count
- 110
Key People
- Jack Lee - CEO
- Sunny Pahk - Chief Business Officer
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team, including CEO Jack Lee, brings over a decade of experience in the MedTech industry.
A leadership team with over 10 years of experience in MedTech indicates a strong foundation for navigating industry challenges and driving innovation.
- Clinical Need
-
Aspect: Very Strong
Summary: Sky Labs addresses a critical need for continuous, non-invasive blood pressure monitoring in managing chronic conditions.
Continuous, non-invasive monitoring is essential for effective management of chronic conditions like hypertension, making Sky Labs' solution highly relevant.
- Competition
-
Aspect: First mover
Summary: Sky Labs is a pioneer in ring-type continuous blood pressure monitoring devices.
As a first mover, Sky Labs has the advantage of setting industry standards but may face challenges in educating the market and establishing trust.
- Technical Challenge
-
Aspect: Complex
Summary: Developing accurate, continuous, non-invasive blood pressure monitoring technology is technically complex.
Ensuring accuracy and reliability in continuous, non-invasive monitoring requires overcoming significant technical hurdles, which can impact development timelines and costs.
- Patent
-
Aspect: Strong
Summary: Sky Labs holds multiple patents related to their CART series devices.
Holding multiple patents indicates a commitment to innovation and provides a barrier to entry for competitors, enhancing the company's market position.
- Financing
-
Aspect: Well-funded
Summary: Sky Labs has secured significant funding, including a recent Series C round totaling KRW 20.7 billion.
Securing substantial funding enables the company to invest in R&D, clinical trials, and market expansion, which are critical for success in the MedTech industry.
- Regulatory
-
Aspect: 510k/PMA
Summary: CART BP has received approval from South Korean regulators and is seeking FDA and CE approvals.
Achieving regulatory approvals in key markets like the US and Europe is essential for product commercialization and building trust with healthcare providers and patients.
Opportunity Rollup
- Odds of Success
- 2.9
- Peak Market Share
- 3.6
- Segment CAGR
- 9.1%
- Market Segment
- Cardiac Rhythm Management Devices
- Market Sub Segment
- Wearable Blood Pressure Monitors
Year Post Launch | Market Penetration (%) |
---|---|
1 | 0.18 |
2 | 0.54 |
3 | 1.26 |
4 | 2.52 |
5 | 3.60 |
Key Takeaway
Sky Labs' innovative CART series addresses a critical need in chronic disease management, supported by strong leadership and financial backing, positioning it well in the growing wearable medical device market.